Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX).

Full DD Report for EGRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: EGRX)

Wired News - FDA Granted Approval to Eagle Pharma's Bendamustine Hydrochloride RTD Solution in a 500ml Admixture
Stock Monitor: Catalyst Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Eagle Pharma, Inc. (NASDAQ: EGRX ) ("Eagle"), all you need to do is sign up now by clicking the following link www.active-investors.com/re...
Source: ACCESSWIRE IA
Date: May, 18 2018 07:40
Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Corcept Therapeutics Incorporat...
Source: GlobeNewswire
Date: May, 17 2018 07:50
FDA approves Eagle Pharmaceuticals' RTD HCI solution in a 500ml admixture
FDA has granted final approval for Eagle Pharmaceuticals' (NASDAQ: EGRX ) ready-to-dilute (RTD) bendamustine hydrochloride ((HCl)) solution in a 500ml admixture for the treatment of patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. More news on: Eagle P...
Source: SeekingAlpha
Date: May, 16 2018 07:46
Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture
-- Eagle to ship 500ml admixture product immediately -- Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Eagle’s ready-to-dilute (RTD)...
Source: Business Wire
Date: May, 16 2018 06:50
Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2018 Results - Earnings Call Transcript
Start Time: 08:30 End Time: 09:11 Eagle Pharmaceuticals, Inc. (EGRX) Q1 2018 Earnings Conference Call May 10, 2018, 08:30 AM ET Executives Scott Tarriff - CEO Pete Meyers - CFO Ilanit Allen - In-Site Communications, Inc., IR Analysts David Amsellem - Piper Jaffray Ran...
Source: SeekingAlpha
Date: May, 10 2018 13:47
Eagle Pharmaceuticals misses by $0.14, misses on revenue
Eagle Pharmaceuticals (NASDAQ: EGRX ): Q1 EPS of $0.55 misses by $0.14 . Revenue of $46.6M (-39.3% Y/Y) misses by $2.28M . Press Release More news on: Eagle Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: May, 10 2018 06:52
Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results
-- Eagle requested final FDA approval of its tentatively approved bendamustine hydrochloride 500ml; launch to be scheduled upon approval -- Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq: EGRX) today announced its financial results for the t...
Source: Business Wire
Date: May, 10 2018 06:50
Notable earnings before Thursday's open
ACIW , AMCX , BAM , BIOS , BPMP , BTG , CHH , CLNS , CRL , DEPO , DESP , DSX , DUK , ECOM , EGRX , ENB , GDS , HIMX , HL , ICL , KELYA , KLIC , LHO , MDP , MGA , MIXT , MMS , NICE , NOMD , OMI , PBH , PEGI , PQG , RDUS , SATS , SND , SNR , SPH , TGI , ...
Source: SeekingAlpha
Date: May, 09 2018 17:30
Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018
Eagle Pharmaceuticals, Inc. ("Eagle" or “the Company”) (Nasdaq: EGRX) today announced that the Company will release its 2018 first quarter financial results on Thursday, May 10, 2018, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Fi...
Source: Business Wire
Date: May, 01 2018 16:30
Eagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care Conference
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 43rd Annual Deutsche Bank Health Care Conference as follows: The presentation will be webcast live at the aforementioned ti...
Source: Business Wire
Date: April, 30 2018 16:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1868.4968.5969.4967.55281,870
2018-05-1768.4968.5969.4967.55281,870
2017-02-0268.1068.6970.4668.10236,301
2017-02-0169.8068.3569.8067.43237,790
2017-01-3165.7369.2169.6764.286235,730

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-237,76625,00331.0603Cover
2018-05-2239,81283,28447.8027Short
2018-05-2137,07660,32461.4614Short
2018-05-1844,97676,61458.7047Short
2018-05-1742,45166,21764.1089Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EGRX.


About Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX)

Logo for Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: EGRX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 28 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 20 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: EGRX)

      Daily Technical Chart for (NASDAQ: EGRX)


      Stay tuned for daily updates and more on (NASDAQ: EGRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: EGRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      Monsta Trader
      @MonstaTrader

       

       


      Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EGRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of EGRX and does not buy, sell, or trade any shares of EGRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/